In Vivo Screening Data Summary

NCI In Vivo Screening Data

P1798 Lymphosarcoma (subcutaneous) in CD2F1 (CDF1) mice

NSC 755
CAS 50-44-2
Mercaptopurine; 6-Purinethiol; 6-Mercaptopurine

Chemical Data
Schedule (route) Endpoint Vehicle Dose Treated/Control (%) Observations
Q01DX010 (ip) mean tumor weight alkali diluted with saline 10.0 mg/kg/injection 90.0 Antitumor endpoint evaluated on day 12; 06/06 animals surviving on tox evaluation day (usually day 5)
Q01DX010 (ip) mean tumor weight alkali diluted with saline 20.0 mg/kg/injection 49.0 Antitumor endpoint evaluated on day 12; 06/06 animals surviving on tox evaluation day (usually day 5)
Q01DX010 (ip) mean tumor weight alkali diluted with saline 20.0 mg/kg/injection 100.0 Antitumor endpoint evaluated on day 12; 06/06 animals surviving on tox evaluation day (usually day 5)
Q01DX010 (ip) mean tumor weight alkali diluted with saline 40.0 mg/kg/injection 76.0 Antitumor endpoint evaluated on day 12; 06/06 animals surviving on tox evaluation day (usually day 5)
Q01DX010 (ip) mean tumor weight alkali diluted with saline 40.0 mg/kg/injection 108.0 Antitumor endpoint evaluated on day 12; 06/06 animals surviving on tox evaluation day (usually day 5)
Q01DX010 (ip) mean tumor weight alkali diluted with saline 80.0 mg/kg/injection 0.0 Antitumor endpoint evaluated on day 12; 03/06 animals surviving on tox evaluation day (usually day 5)
Q01DX010 (ip) mean tumor weight alkali diluted with saline 80.0 mg/kg/injection 35.0 Antitumor endpoint evaluated on day 12; 05/06 animals surviving on tox evaluation day (usually day 5)